ENYO PHARMA
ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public). The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and the BSL4 laboratory Inserm-Jean Mérieux. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and devel... oped a unique platform for the identification of intracellular therapeutic targets and molecules. The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
ENYO PHARMA
Industry:
Biopharma Biotechnology Medical
Founded:
2014-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.enyopharma.com
Total Employee:
11+
Status:
Active
Contact:
33437700219
Email Addresses:
[email protected]
Total Funding:
64.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Investors List
InnoBio
InnoBio investment in Series B - ENYO Pharma
Bpifrance
Bpifrance investment in Series B - ENYO Pharma
Morningside Venture Investments
Morningside Venture Investments investment in Series B - ENYO Pharma
OrbiMed
OrbiMed investment in Series B - ENYO Pharma
Sofinnova Investments
Sofinnova Investments investment in Series B - ENYO Pharma
Inserm Transfert Initiative
Inserm Transfert Initiative investment in Series B - ENYO Pharma
Andera Partners
Andera Partners investment in Series B - ENYO Pharma
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - ENYO Pharma
Sofinnova Partners
Sofinnova Partners investment in Series A - ENYO Pharma
Official Site Inspections
http://www.enyopharma.com Semrush global rank: 8.82 M Semrush visits lastest month: 249
- Host name: 98-116-176-185.rev.solware.fr
- IP address: 185.116.176.98
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "ENYO Pharma"
Company overview - ENYO Pharma
History of ENYO Pharma with virus biomimetism. Our story began in 2014 when experts in virus-host protein interactions from the French Infectiology Research Center (Inserm) in Lyon, …See details»
About us – ENYO Pharma
ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome.See details»
ENYO Pharma - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 33437700219 ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology …See details»
ENYO Pharma - LinkedIn
ENYO Pharma Biotechnology Research Lyon, Rhône-Alpes 7,568 followers Developing therapeutics for diseases with impaired kidney functionSee details»
ENYO Pharma SA - Drug pipelines, Patents, Clinical trials - Synapse
Www.enyopharma.com. Startups | Holding Company | 2014 | France | 10-50 | www.enyopharma.com. Last update 19 Sep 2024. Overview. Pipeline. Deal. Translational …See details»
Enyo Pharma Announces Move to New Corporate Headquarters
Oct 3, 2019 Investor Relations: Tel: +33 (0)4 37 70 02 27 [email protected] Media Relations: Annie-Florence Loyer, NewCap Media +33 (0)1 44 71 00 12/ +33 (0)6 88 20 …See details»
ENYO Pharma Company Profile - Office Locations, Competitors
ENYO Pharma has 5 employees at their 1 location and $78 m in total funding,. See insights on ENYO Pharma including office locations, competitors, revenue, financials, executives, …See details»
ENYO Pharma Company Profile 2024: Valuation, Funding
Www.enyopharma.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. Bioserra 1 Bâtiment B; 60 Avenue Rockefeller; 69008 Lyon; …See details»
Management - ENYO Pharma
Management. ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.See details»
ENYO Pharma - Overview, News & Similar companies - ZoomInfo
Nov 4, 2021 ENYO Pharma contact info: Phone number: +33 437700219 Website: www.enyopharma.com What does ENYO Pharma do? ENYO is a clinical-stage …See details»
Enyo Pharma - VentureRadar
Similar Companies: Cocrystal Pharma USA Publicly Traded Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that …See details»
ENYO Pharma - Products, Competitors, Financials, Employees ...
About ENYO Pharma. ENYO Pharma develops therapeutics in the healthcare sector, specifically for diseases with impaired kidney function. The company's main offerings include treatments …See details»
ENYO Pharma Announces a €39 Million Series C Financing and …
Jan 3, 2024 Investor Relations EnyoPharma Tel: +33 (0)4 37 70 02 27 [email protected]. Media Relations Annie-Florence Loyer, NewCap Media …See details»
ENYO Pharma Announces a €39 Million Series C Financing and …
LYON, France, January 03, 2024--ENYO Pharma ("ENYO") announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug …See details»
ENYO Pharma
Alport Connect 2024, the annual Alport syndrome patient and family meeting in US . 27-28 July 2024 Denver, CA. ENYO Pharma is sponsoring and will attend Alport Connect 2024 organized …See details»
ENYO Pharma Announces Positive Vonafexor (EYP001 ... - Business …
Jul 28, 2021 Investor Relations: Tel: +33 (0)4 37 70 02 27 [email protected] Media Relations: Annie-Florence Loyer, NewCap Media +33 (0)1 44 71 00 12/ +33 (0)6 88 20 …See details»
ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line …
Jul 30, 2021 Investor Relations: Tel: +33 (0)4 37 70 02 27 [email protected] Media Relations: Annie-Florence Loyer, NewCap Media +33 (0)1 44 71 00 12/ +33 (0)6 88 20 …See details»
ENYO Pharma – Developing therapeutics for diseases with …
Développer des thérapies pour les maladies rénales chroniques. ENYO Pharma est une société biopharmaceutique au stade clinique. Notre mission est de développer des molécules aux …See details»
ENYO PHARMA ANNONCE UN FINANCEMENT DE SÉRIE C DE 39 …
Jan 3, 2024 Investor Relations EnyoPharma: Tel: +33 (0)4 37 70 02 27 [email protected] Media Relations: Annie-Florence Loyer - NewCap Media …See details»